211 related articles for article (PubMed ID: 27854207)
1. Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual.
Butala BN; Kang A; Guron J; Brandom BW
J Neuromuscul Dis; 2016 Mar; 3(1):115-119. PubMed ID: 27854207
[TBL] [Abstract][Full Text] [Related]
2. Postoperative malignant hyperthermia confirmed by calcium-induced calcium release rate after breast cancer surgery, in which prompt recognition and immediate dantrolene administration were life-saving: a case report.
Miyazaki N; Kobayashi T; Komiya T; Okada T; Ishida Y; Fukui H; Ogihara Y; Uchino H
J Med Case Rep; 2021 Apr; 15(1):201. PubMed ID: 33863374
[TBL] [Abstract][Full Text] [Related]
3. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.
Cherednichenko G; Ward CW; Feng W; Cabrales E; Michaelson L; Samso M; López JR; Allen PD; Pessah IN
Mol Pharmacol; 2008 Apr; 73(4):1203-12. PubMed ID: 18171728
[TBL] [Abstract][Full Text] [Related]
4. Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis.
de Lima Silva EV; Donis KC; Machado FRC; Simão Medeiros L; Aschoff CAM; de Souza CFM; Poswar FO; Saute JAM
J Neuromuscul Dis; 2023; 10(6):1145-1149. PubMed ID: 37781817
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological distinction between dantrolene and ryanodine binding sites: evidence from normal and malignant hyperthermia-susceptible porcine skeletal muscle.
Palnitkar SS; Mickelson JR; Louis CF; Parness J
Biochem J; 1997 Sep; 326 ( Pt 3)(Pt 3):847-52. PubMed ID: 9307036
[TBL] [Abstract][Full Text] [Related]
6. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications.
Nelson TE; Lin M; Zapata-Sudo G; Sudo RT
Anesthesiology; 1996 Jun; 84(6):1368-79. PubMed ID: 8669678
[TBL] [Abstract][Full Text] [Related]
7. Malignant hyperthermia.
Halliday NJ
J Craniofac Surg; 2003 Sep; 14(5):800-2. PubMed ID: 14501352
[TBL] [Abstract][Full Text] [Related]
8. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
9. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
[TBL] [Abstract][Full Text] [Related]
10. Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle.
Sudo RT; Carmo PL; Trachez MM; Zapata-Sudo G
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):308-16. PubMed ID: 18047479
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs.
Schütte JK; Becker S; Burmester S; Starosse A; Lenz D; Kröner L; Wappler F; Gerbershagen MU
Eur J Anaesthesiol; 2011 Apr; 28(4):256-64. PubMed ID: 21513076
[TBL] [Abstract][Full Text] [Related]
12. [Dantrolene. Pharmacological and therapeutic aspects].
Gerbershagen MU; Fiege M; Krause T; Agarwal K; Wappler F
Anaesthesist; 2003 Mar; 52(3):238-45. PubMed ID: 12666006
[TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia.
Denborough M
Lancet; 1998 Oct; 352(9134):1131-6. PubMed ID: 9798607
[TBL] [Abstract][Full Text] [Related]
14. Dantrolene stabilizes domain interactions within the ryanodine receptor.
Kobayashi S; Bannister ML; Gangopadhyay JP; Hamada T; Parness J; Ikemoto N
J Biol Chem; 2005 Feb; 280(8):6580-7. PubMed ID: 15611117
[TBL] [Abstract][Full Text] [Related]
15. Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno CA; Kraeva N; Zvaritch E; Jungbluth H; Voermans NC; Riazi S
Anesth Analg; 2023 Mar; 136(3):569-577. PubMed ID: 36201369
[TBL] [Abstract][Full Text] [Related]
16. [Malignant hyperthermia--a hereditary and potentially life-threatening condition].
Haugen T; Toft M; Müller CR; Aasly J
Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2792-4. PubMed ID: 16244682
[TBL] [Abstract][Full Text] [Related]
17. The effects of dantrolene in the presence or absence of ryanodine receptor type 1 variants in individuals predisposed to malignant hyperthermia.
Noda Y; Mukaida K; Miyoshi H; Nakamura R; Yasuda T; Saeki N; Nishino I; Tsutsumi YM
Anaesth Intensive Care; 2022 Jul; 50(4):312-319. PubMed ID: 35549722
[TBL] [Abstract][Full Text] [Related]
18. Dantrolene requires Mg
Choi RH; Koenig X; Launikonis BS
Proc Natl Acad Sci U S A; 2017 May; 114(18):4811-4815. PubMed ID: 28373535
[TBL] [Abstract][Full Text] [Related]
19. Malignant hyperthermia.
Ali SZ; Taguchi A; Rosenberg H
Best Pract Res Clin Anaesthesiol; 2003 Dec; 17(4):519-33. PubMed ID: 14661655
[TBL] [Abstract][Full Text] [Related]
20. [Suspected case of postoperative malignant hyperthermia treated with dantrolene one week after neurosurgery].
Itoh K; Nishibe S; Usuda Y; Kitamura A
Masui; 2014 Oct; 63(10):1153-5. PubMed ID: 25693350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
